Based on these highly significant improvements in outcomes over standard doses of radiotherapy alone and the relatively mild side effects with complete tumor shrinkages reported in 70/71 (98%) primary breast cancers up to 5 cm diameter, a Phase II RCT of 84 participants is currently underway by the Institute of Cancer Research in the UK ( https://clinicaltrials.gov/ct2/show/NCT02757651 ).
← all excerpts
Intratumoral pro-oxidants promote cancer immunotherapy by recruiting and reprogramming neutrophils to eliminate tumors.
1
—
—